Welcome to our dedicated page for Organovo Holdings news (Ticker: $ONVO), a resource for investors and traders seeking the latest updates and insights on Organovo Holdings stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Organovo Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Organovo Holdings's position in the market.
Organovo Holdings (Nasdaq: ONVO) presented promising data at Digestive Disease Week (DDW2024) in Washington, D.C., showcasing the potential of FXR314 for treating inflammatory bowel disease (IBD). The study highlights the benefits of combining FXR314, a non-steroidal, non-bile acid FXR agonist, with tofacitinib, a JAK inhibitor. Results showed improvements in intestinal barrier function, inflammation, and fibrosis in 3D and preclinical IBD models. Both compounds, when used at optimal and sub-efficacious concentrations, demonstrated enhanced therapeutic effects. FXR314 alone also showed similar efficacy to approved therapies. These findings support the potential of FXR314 for monotherapy and combination therapy in future clinical studies.
Organovo, a clinical-stage biotechnology company (Nasdaq: ONVO), announces its presentation at Digestive Diseases Week (DDW2024) in Washington, D.C., from May 18-21, 2024. The company will present data on its lead drug, FXR314, a combination therapy with tofacitinib for inflammatory bowel disease (IBD) and ulcerative colitis. The poster titled 'Combination therapy of the FXR agonist FXR314 with tofacitinib in models of inflammatory bowel disease' will be showcased on May 18, 2024, at 12:30 EDT. This event is a significant opportunity for Organovo to engage with prescribers and potential partners.
Organovo Holdings, Inc. announced the pricing of a public offering of 6,562,500 shares of common stock and common warrants, expecting gross proceeds of $5.25 million. The offering price per share is $0.80 with common warrants exercisable at the same price. The offering is set to close on May 13, 2024. JonesTrading Institutional Services is the placement agent for the offering.
